Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment

Exclusion Criteria

• •Hypersensitivity to hyaluronate or. HEALON5® PRO OVD
• •Participation in another interventional study within 8 weeks of enrolment or planned to occur during this study.
• •Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped prior to surgery and recommenced only after satisfactory day 1 post-operative review.
• •Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.
• •Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease.
• •Study eye:
• •Presence of proliferative vitreoretinopathy (PVR) or any tractional RD
• •Previous vitreoretinal surgery, open-globe injury or endophthalmitis
• •Aphakia
• •Previous or current congenital cataract
• •Previous or current suprachoroidal haemorrhage
• •Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5 into the suprachoroidal space (detail the specific reason for exclusion in the source documents)
• •Presence of other ocular co-morbidity that, in the opinion of the investigator, is likely to prevent an accurate assessment of retinal attachment
• •Current intraocular inflammation other than mild cellular activity thought to be secondary to RD
• •Current ocular or periocular infection other than blepharitis